GB202202628D0 - Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety - Google Patents

Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety

Info

Publication number
GB202202628D0
GB202202628D0 GBGB2202628.0A GB202202628A GB202202628D0 GB 202202628 D0 GB202202628 D0 GB 202202628D0 GB 202202628 A GB202202628 A GB 202202628A GB 202202628 D0 GB202202628 D0 GB 202202628D0
Authority
GB
United Kingdom
Prior art keywords
tissue
organic
targeting moiety
specific targeting
novel use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2202628.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Priority to GBGB2202628.0A priority Critical patent/GB202202628D0/en
Publication of GB202202628D0 publication Critical patent/GB202202628D0/en
Priority to PCT/GB2023/050424 priority patent/WO2023161648A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB2202628.0A 2022-02-25 2022-02-25 Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety Ceased GB202202628D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2202628.0A GB202202628D0 (en) 2022-02-25 2022-02-25 Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety
PCT/GB2023/050424 WO2023161648A1 (en) 2022-02-25 2023-02-24 Novel use and method comprising il-2 and a tissue- or organ-specific targeting moiety

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2202628.0A GB202202628D0 (en) 2022-02-25 2022-02-25 Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety

Publications (1)

Publication Number Publication Date
GB202202628D0 true GB202202628D0 (en) 2022-04-13

Family

ID=81075481

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2202628.0A Ceased GB202202628D0 (en) 2022-02-25 2022-02-25 Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety

Country Status (2)

Country Link
GB (1) GB202202628D0 (en)
WO (1) WO2023161648A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410512A1 (en) * 2000-06-09 2001-12-13 University Of Florida Research Foundation, Inc. Recombinant aav vectors for gene therapy of obesity
JP2005514403A (en) * 2001-12-21 2005-05-19 ザ ソーク インスティテュート フォー バイオロジカル スタディーズ Targeted retrograde gene delivery to motor neurons
ES2752191T3 (en) * 2012-02-17 2020-04-03 Childrens Hospital Philadelphia Compositions and methods with AAV vectors for gene transfer to cells, organs and tissues
WO2016122943A2 (en) * 2015-01-26 2016-08-04 The Research Institute At Nationwide Children's Hospital Compounds, compositions, and methods for using hla-f
US11905533B2 (en) * 2017-12-19 2024-02-20 The University Of North Carolina At Chapel Hill Methods and compositions for delivery of viral vectors across the blood-brain barrier
GB201912863D0 (en) 2019-09-06 2019-10-23 Babraham Inst Novel method
JP2023506253A (en) * 2019-12-16 2023-02-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Compositions and methods for treating neuromuscular disorders

Also Published As

Publication number Publication date
WO2023161648A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
GB202202628D0 (en) Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety
EP4061254A4 (en) Targeting guides
GB202118073D0 (en) Novel method and composition comprising IL-2 and a tissue- or organ-specific targeting moiety
GB202306163D0 (en) Use and method
EP4132666A4 (en) A game apparatus
EP4161307A4 (en) A personal protective equipment
EP4240883A4 (en) Maraging steel
EP4176132C0 (en) Method and machine comprising a tamping assembly
KR102356099B9 (en) A jucier and jucier method thereof
GB202307777D0 (en) Method and kit-of-parts
ZA202213833B (en) A protective device and assembling method
GB202006975D0 (en) A method and apparatus for RNA synthesis
GB202215847D0 (en) Part of a protective apparatus and protective apparatus
AU2024902367A0 (en) Eyelash Protectors
GB202019563D0 (en) Appratus and method
GB202405650D0 (en) Hdac6 protacs
AU2022901873A0 (en) Gel blaster accessory
ZA202303070B (en) A binder and its preparation method
AU2022902252A0 (en) Total Fencer
GB202306380D0 (en) Ball-sport training aid
GB202201808D0 (en) Training aid
GB202212978D0 (en) A bookmark
GB202405520D0 (en) A prosthetic hand and associated method
GB202312078D0 (en) Use and method
GB202310225D0 (en) Method and use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)